Stockscreener 앱 받기
31.10
1.21%
-0.38
시간 외 거래:
31.55
0.45
+1.45%
전일 마감가:
$31.48
열려 있는:
$31.48
하루 거래량:
2.02M
Relative Volume:
1.61
시가총액:
$2.44B
수익:
$866.00K
순이익/손실:
$-283.65M
주가수익비율:
-7.2885
EPS:
-4.267
순현금흐름:
$-226.25M
1주 성능:
-18.67%
1개월 성능:
-24.55%
6개월 성능:
-1.83%
1년 성능:
+23.17%
1일 변동 폭
$30.65
$31.70
1주일 범위
$30.39
$41.62
52주 변동 폭
$22.10
$45.14
Celldex Therapeutics Inc Stock (CLDX) Company Profile
명칭
Celldex Therapeutics Inc
전화
908-200-7500
주소
53 FRONTAGE ROAD, HAMPTON
Compare CLDX vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
31.10 | 2.44B | 866.00K | -283.65M | -226.25M | -4.267 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-20 | 업그레이드 | Barclays | Underweight → Overweight |
| 2026-03-23 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-10-13 | 개시 | Barclays | Underweight |
| 2025-04-28 | 개시 | Canaccord Genuity | Buy |
| 2025-03-20 | 개시 | Morgan Stanley | Overweight |
| 2025-02-13 | 개시 | UBS | Buy |
| 2024-10-07 | 개시 | Citigroup | Buy |
| 2024-09-30 | 개시 | Goldman | Neutral |
| 2024-09-27 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | 개시 | Stifel | Buy |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2023-12-20 | 개시 | TD Cowen | Outperform |
| 2023-11-10 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | 개시 | Wells Fargo | Underweight |
| 2021-09-17 | 개시 | Jefferies | Buy |
| 2021-09-10 | 개시 | SVB Leerink | Outperform |
| 2021-07-22 | 개시 | Guggenheim | Buy |
| 2020-02-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-08-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-07 | 개시 | Aegis Capital | Buy |
| 2016-03-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2016-03-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2016-03-07 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2016-03-01 | 개시 | H.C. Wainwright | Buy |
| 2015-08-11 | 재확인 | Brean Capital | Buy |
| 2015-08-11 | 재확인 | Oppenheimer | Outperform |
| 2015-08-11 | 재확인 | ROTH Capital | Buy |
| 2015-06-02 | 재확인 | WBB Securities | Strong Buy |
| 2014-11-17 | 재확인 | ROTH Capital | Buy |
| 2014-03-04 | 재확인 | Oppenheimer | Outperform |
| 2013-07-08 | 재확인 | Cantor Fitzgerald | Buy |
| 2013-03-08 | 재확인 | Cantor Fitzgerald | Buy |
| 2013-02-26 | 재확인 | Oppenheimer | Outperform |
| 2013-01-10 | 재확인 | Cantor Fitzgerald | Buy |
| 2012-10-02 | 재확인 | Oppenheimer | Outperform |
| 2012-09-14 | 재확인 | Cantor Fitzgerald | Buy |
모두보기
Celldex Therapeutics Inc 주식(CLDX)의 최신 뉴스
Yaron Werber: Celldex's Urticaria Drug Won't Carry a Black Box; Amgen Maps a $25 Billion Sjogren's Market - finance.biggo.com
Is Celldex Therapeutics, Inc. (CLDX) the Healthcare Stocks Stock Everyone's About to Talk About? - Kalkine Media
What Do Positive Barzolvolimab Results Mean for Celldex (NASDAQ:CLDX)? - Kalkine Media
H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $64 - Moomoo
Celldex's price target jumps to $88 after positive Phase III trial for chronic urticaria drug. - Pluang
Leerink Partners maintains Outperform rating on Celldex Therapeutics, $88 price target - TradingView
Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success? - Yahoo Finance
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Yahoo Finance
Celldex Therapeutics upgraded to Buy after posi... - Pluang
Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous UrticariaSlideshow (NASDAQ:CLDX) 2026-09-22 - Seeking Alpha
Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results - Benzinga
Celldex's Barzolvolimab Hits Mark in Two Phase 3 Trials for Chronic Hives - finance.biggo.com
CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’ - tradingview.com
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease - Benzinga
Celldex Therapeutics Shares Fall After Phase 3 Readout Despite Positive Trial Results - Quiver Quantitative
4 Biotech Stocks With Key Clinical Readouts Expected This Fall - theglobeandmail.com
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses - Yahoo Finance
Celldex sinks as safety concerns cloud immune drug results - Yahoo Finance
Celldex shares slip 15% as safety concerns cloud skin drug trial win - The Economic Times
Celldex's barzolvolimab hits primary and secondary endpoints in twin Phase III CSU trials - The Pharma Letter
Celldex Shares Rise 8% as Barzolvolimab Meets Primary Endpoints in Two Phase 3 Trials - Yahoo Finance
Celldex stock falls after hives trial data (CLDX:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Celldex reports positive phase 3 trial results for CSU drug By Investing.com - Investing.com Canada
Celldex reports strong Phase 3 data in urticaria - TipRanks
Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria Trials - marketscreener.com
Celldex stock rises after positive phase 3 trial results By Investing.com - Investing.com Canada
Celldex announces Phase 3 barzolvolimab trials meet primary and all key secondary endpoints - TradingView
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 - GlobeNewswire
Celldex Therapeutics stock gains as analysts target USD 56.42 - AD HOC NEWS
Celldex Reports Positive Phase 3 Results for Barzolvolimab - Intellectia AI
Celldex Therapeutics stock gains as analysts lift expectations - AD HOC NEWS
Celldex at Cantor conference: barzolvolimab data loom By Investing.com - Investing.com Canada
Celldex to Present at Upcoming Investor Conference - The Manila Times
Celldex's investor talk will stream online Sept. 10 - Stock Titan
Celldex (CLDX) Q2 2026 Earnings: The Available Earnings Metric Delivers a Beat in Latest Trading; Post-Earnings: The Stock Records a 1.60% Increase at the CloseGuidance Downgrade Alert - dars.gov.et
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) - Prime Publishers, Inc.
Celldex Therapeutics, Inc. Revenue Breakdown – NASDAQ:CLDX - TradingView
Celldex (CLDX) Quarterly Results: Profit Per Share Clears Its Benchmark on the Day; Market Reaction - vinanet.vn
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Celldex (CLDX) Momentum: Adds 0.32% to Close at $41.92 in the Current Update; Range Check - vinanet.vn
Celldex Therapeutics, Inc. $CLDX Shares Acquired by Bank of America Corp DE - MarketBeat
Celldex Therapeutics (CLDX) Slips 1.55% to $41.95 as Clinical-Stage Biotech ConsolidatesMomentum Surge Alerts - vinanet.vn
Kynam Capital (CLDX) group discloses 6.78% Celldex Therapeutics ownership stake - Stock Titan
T. Rowe Price Associates (CLDX) discloses 6.0% Celldex Therapeutics ownership on Schedule 13G - Stock Titan
Sei Investments Co. Purchases Shares of 38,152 Celldex Therapeutics, Inc. $CLDX - MarketBeat
Why Celldex Therapeutics (CLDX) Is Up 10.7% After Wider Losses And Barzolvolimab Phase 3 Progress - Sahm
HC Wainwright Issues Optimistic Forecast for CLDX Earnings - MarketBeat
Quantinno Capital Management LP Buys 42,158 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 1-Year HighTime to Buy? - MarketBeat
Assenagon Asset Management S.A. Buys 642,171 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics Inc (CLDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):